SHC
Sotera Health Co.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$16.56
+3.28%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.2B | 1.2B | 1.1B | 1.0B | 1.0B |
| Cost of Revenue | 561.0M | 518.1M | 498.1M | 472.1M | 446.7M |
| Gross Profit | 668.7M | 645.5M | 602.3M | 577.2M | 557.0M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 247.2M | 252.8M | 242.6M | 236.7M | 245.7M |
| General & Admin Expense | 132.3M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (21.7M) | — | 62.0M | 63.8M | 62.9M |
| Total Operating Expenses | 225.5M | 252.8M | 304.7M | 300.5M | 308.7M |
| Cost and Expenses | 786.5M | 770.8M | 802.8M | 772.6M | 755.3M |
| Operating Income (EBIT) | 443.2M | 392.8M | 297.6M | 276.7M | 248.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 138.3M | 155.7M | 164.7M | 142.9M | 80.1M |
| Net Interest Income | (138.3M) | (155.7M) | (164.7M) | (142.9M) | (80.1M) |
| Other Non-Op Income/Expense | (168.3M) | (245.3M) | (183.8M) | (170.7M) | (491.5M) |
| Non-Operating Income (excl Interest) | 30.0M | 89.5M | 19.1M | 27.8M | 411.3M |
| EBT (Pre-Tax Income) | 274.9M | 147.5M | 113.9M | 106.0M | (243.1M) |
| Income Tax Expense | 101.4M | 69.6M | 69.5M | 54.7M | (9.5M) |
| Bottom Line | |||||
| Net Income | 173.5M | 77.9M | 44.4M | 51.4M | (233.6M) |
| Earnings from Cont. Ops | 173.5M | 77.9M | 44.4M | 51.4M | (233.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 173.5M | 77.9M | 44.4M | 51.4M | (233.6M) |
| Per Share | |||||
| Basic EPS | $0.60 | $0.27 | $0.16 | $0.18 | ($0.83) |
| Diluted EPS | $0.60 | $0.27 | $0.16 | $0.18 | ($0.83) |
| Revenue Per Share | $4.30 | $4.10 | $3.89 | $3.73 | $3.58 |
| Shares | |||||
| Basic Shares Outstanding | 286.0M | 284.0M | 282.8M | 281.0M | 280.1M |
| Diluted Shares Outstanding | 289.2M | 286.4M | 284.9M | 283.2M | 280.1M |
| Profitability Metrics | |||||
| EBITDA | 542.4M | 442.3M | 442.2M | 406.8M | (17.4M) |
| D&A | 129.2M | 139.0M | 163.6M | 157.9M | 145.6M |
| EBIT | 413.2M | 303.2M | 278.6M | 248.9M | (163.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026